1. Introduction
===============

Respiratory tract infections (RTI) are extremely common and in developed countries, RTI account for over 20% of all medical consultations ([@b1-etm-0-0-8704]). In children, the figures are even higher. Worldwide, every year, over 1 million children and infants under 5 years die from acute respiratory infections ([@b2-etm-0-0-8704]), this disease represents in developing countries the cause of death of 30% of children under five years ([@b3-etm-0-0-8704],[@b4-etm-0-0-8704]). When RTI have an increased frequency, over 60% of the cases have a primary immunodeficiency in humoral immunity. A recent study has shown that deficiencies in immunoglobulin (Ig) synthesis and secretion are proven in abnormal levels of IgG, IgA and IgM ([@b5-etm-0-0-8704]). Not only Igs are affected, but also other immune molecules. In children diagnosed with RTI decreased levels of proinflammatory cytokines were identified, mainly interferon (IFN)-γ ([@b6-etm-0-0-8704]). IFN-stimulated genes (ISGs) are highly involved in the antiviral immune response ([@b7-etm-0-0-8704]).

In bacterial infection multidrug-resistant (MDR) processes are involved in the difficult-to-treat pathogens ([@b8-etm-0-0-8704]), but in viral infections this process has just a collateral importance because a substantial proportion of RTI are actually acute viral infections. The treatment of these infections relies on antivirals and on relieving disease symptoms. However, similarly to bacterial infections, antiviral agents would conserve viral proteins, that will induce a selective pressure on the viral particle, leading to development of antiviral resistance ([@b11-etm-0-0-8704],[@b12-etm-0-0-8704]).

As the best 'treatment' is prevention, in viral infections vaccination is the best approach, but the pace of vaccine development is slow and it has to overcome various hurdles, e.g., antigenic variations, low efficacy, short-term immune responses. As we are now faced with one of the major outbreaks of viral infection of the modern history, vaccine development workflow can not control the infection spreading ([@b13-etm-0-0-8704]). Therefore, novel approaches are tested and designed. One of these novel approaches is passive immunization ([@b14-etm-0-0-8704]) where mainly polyclonal antibodies derived from several sources (e.g., sera of immunized animals, immunized humans, convalescing patients) can be used ([@b15-etm-0-0-8704],[@b16-etm-0-0-8704]). In this case also the use of polyclonal antibodies has some hurdles such as standardization and patient safety. Monoclonal antibodies (mAbs) is the best choice but their production costs is still very high, as an example the high costs of monoclonal antidodies used in melanoma therapies ([@b17-etm-0-0-8704]). The costs increase further in respiratory infection because there are viral escape mutants that would need additional mAbs ([@b18-etm-0-0-8704]). Therefore in this complex picture of immunity in viral infection an interesting approach has risen in recent years - the use of specific IgY. IgY is produced by birds, reptiles and amphibians with a function similar to that of mammalian IgGs ([@b19-etm-0-0-8704]). IgYs are circulating in the sera as IgGs, but in addition they accumulate 100 times more concentrated in the egg yolk and are passed to the developing embryo ([@b20-etm-0-0-8704]).

IgY antibodies extracted from hen eggs have been used in bacterial ([@b21-etm-0-0-8704]) and viral infections therapy ([@b22-etm-0-0-8704]). It has some favorable characteristics: it is well tolerated due to human diet, it can be used in individuals who are allergic to eggs because the purified IgY is depleted of egg albumin ([@b23-etm-0-0-8704]), it has a good tolerability. Moreover, the systemic administration has shown the capability of specific IgY raised against viruses to protect against actual diseases. For example, in pig model IgY protected against Rotavirus infection ([@b24-etm-0-0-8704]). Systemic and local administration of IgY in mammals have shown that an anti-IgY antibody response was generated, mainly consisting of the IgG subclass. These reports show that IgY is antigenic but this antibody molecule cannot bind to mammalian Fc receptors, so adverse effects on this route are minimal ([@b25-etm-0-0-8704]). More than 20 years ago it was shown that in mouse model administration of IgY, purified or not, did not induce an IgE response, hence no allergic response ([@b26-etm-0-0-8704]) and due to the fact that IgY does not link to the human complement system or Fc receptors, additional inflammation upon administration is minimal ([@b27-etm-0-0-8704]). IgY action is to bind to the bacteria or virus, and facilitate the elimination of the agent through the gut preventing bacterial or viral replication and spread ([@b28-etm-0-0-8704]). Passive immunization with IgY can be given in humans with active infection as they develop a rapid response. Moreover, immature infants or immune-suppressed patients can also benefit from this passive immunization ([@b29-etm-0-0-8704],[@b30-etm-0-0-8704]). IgY has a high content of sialic acid ([@b31-etm-0-0-8704]), with increased half-life ([@b32-etm-0-0-8704]) that suggests IgY to have a longer circulating half-life, and hence increased anti-pathogen action and increased efficacy against infections ([@b33-etm-0-0-8704]).

We aim to highlight in this review that in the quest to find quick and effective anti-viral therapies, specific IgY can be another possibility to fight against viral RTI.

2. IgY an established immune-fighter - is there something new on its (bio) applications?
========================================================================================

An antigen attack upon host is followed by Igs or antibodies production in humans, process sustained by plasma cells developing thus the humoral immunity ([@b34-etm-0-0-8704]). Antibodies engage in the fight against the antigen by an array of mechanisms: neutralization, fixation of pathogen, complement activation or acting like receptors on B cell surface ([@b35-etm-0-0-8704]). Igs have interspecies differences regarding their structural particularities or classes, thus the term IgY comes from egg yolk where this Ig type is produced for assuring immunity in the hen progeny. IgY represents the functional equivalent of human IgG ([@b29-etm-0-0-8704]). In the last decade, IgY has gained scientific attention due to its distinctive biological actions largely emerged from its structural particularities ([@b36-etm-0-0-8704]).

Currently there are several commercial applications where Igs are fully explored in diagnostic and therapy monitoring assays.

### Fighting against bacterial infections

Immunization of avian with specific bacterial antigens such as *Salmonella sp.* would provide a specific IgY against the inductor antigen. Moreover, due its high stability and structural unique features IgY has been applied successfully in diagnostic, prophylactic and therapeutic purposes as well as immunochemical reagents ([@b34-etm-0-0-8704]).

In addition to chicken models, there are other hands-on and inexpensive models such as the quail model where production of specific IgYs against *Salmonella sp.* has been recently reported. These quail anti-*Salmonella sp.* IgYs exhibit a high specificity to their matching immunogens, having the potential to eradicate enterobacterial pathogens. In addition, the oral ingestion of IgYs represent an efficient alternative for annihilation of gastrointestinal pathogens as *Salmonella typhimurium* and *Salmonella enteritidis*, bacterial species that raise major concern in health and food industry ([@b37-etm-0-0-8704]).

IgYs has also been proposed as a strategy for combating infections caused by *Pseudomonas aeruginosa* known as a common nosocomial pathogen having antibiotic resistance and a frequent infection in acute pneumonia and severely burned patients. A protein called PcrV is a vital part of killing machinery represented by the type III secretion system of *P. aeruginosa* and therefore PcrV is viewed as a target for neutralizing this infectious agent. Thus, recently recombinant PcrV was used for raising specific IgY. These antibodies displayed a protective effect in both acute pneumonia and burn wound models and moreover IgY anti-PcrV has augmented opsonization capacity and bacterial killing activity of host cells ([@b38-etm-0-0-8704]). In fact the augmentation of phagocytic killing via IgY was previously explored in an *in vitro* study targeting *P. aeruginosa* infection in cystic fibrosis (CF) patients. IgY against *P. aeruginosa* fulfill their function by opsonizing the pathogen and thus enhancing the neutrophils respiratory burst while further enabling bacterial killing. It was suggested that prophylaxis with anti-*P. aeruginosa* IgY could lift the innate immunity of CF patients aiding host neutrophils to rapidly clear the bacterial agent ([@b39-etm-0-0-8704]).

In CF the principal contributor of pulmonary failure is the chronic infection with *P. aeruginosa* biofilm, which constantly attracts and activates neutrophils sustaining the continuous inflammation. It is suggested that IgY favors bacteria to form aggregates and increase their hydrophobicity enhancing bacterial killing by neutrophils *via* phagocytosis ([@b40-etm-0-0-8704]).

Passive immunization with IgY anti-*P. aeruginosa* could reduce the initial airway settlement with *P. aeruginosa* in CF patients. Thus in a Balb/c murine *P. aeruginosa* pneumonia model administration of specific IgY significantly reduced the bacterial load at 24 h after infection along with alleviating the clinical symptoms; in addition an inflammatory cytokine pattern was noted revealing the lung inflammation decrease suggesting that immune-prophylaxis with anti-*P. aeruginosa* IgY may also function as an adjuvant to antibiotics in lowering primary colonization of lungs ([@b21-etm-0-0-8704]). In parasitic diseases the possible role of IgY in early diagnosis and therapeutics has been tackled by attempting to obtain polyclonal IgY against parasitic antigens suitable for immunotherapeutic purposes. Although further studies in animal models are indispensable and obtaining a monoclonal IgY anti-parasitic antigens are envisaged, it became obvious that IgY could stand for immunoassay designing also in parasitology area ([@b41-etm-0-0-8704]).

In immunodiagnostic methods, IgY is an excellent tool in assays involving mammalian sera, due to the discriminative properties of IgY compared to mammalian IgG. IgY has immunological properties which makes it very distinct from mammalian IgG but at the same time very affordable for a plenty of immunological approaches. Foremost, by lacking the hinge region, IgY is less structurally flexible than IgG and retains a different protein content, these structural differences sustaining the differences in immunological behavior ([@b42-etm-0-0-8704]). IgY has poor cross-reactivity to mammalian IgG, does not activate the complement system similar to IgM/IgG and lacks the reactivity with mammalian Fc receptor ([@b43-etm-0-0-8704]).

However, there are still incomplete data regarding the three-dimensional structure of Fc-IgY raising the question whether IgY shares a conformational status similar to IgM and IgE whose Fc regions are significantly flexible. However, the evolutionary distance between mammals and birds made possible the feasible generation of IgY against conserved mammal proteins. Thus, the molecular particularities of IgY raised several functional advantages recommending IgY as a versatile tool in biotechnological research, diagnostics and therapeutics ([@b29-etm-0-0-8704]). One very practical utility is that IgY can be used to generate a specific antibody when an antigen comes in small amounts and additionally is low immunogenic in mammals host ([@b44-etm-0-0-8704]).

IgY can be generated at low-costs in considerable amounts through an ecologically friedly approach because it is produced in egg yolk so no additional procedures on animals are needed. There are several IgY isolation methods available, mostly based on precipitation from egg extracts using ammonium sulfate or polyethylene glycol although protein impurities still remains in the sample of interest, in addition to time consuming and complexity required ([@b45-etm-0-0-8704],[@b46-etm-0-0-8704]). Chromatographic methods have become very popular in recent years because this methodology generates highly active pure products useful for biomedical applications. A study published in 2020 reports IgY fragment separations by ion exchange column using DEAE-Sepharose leading to Fab and Fc fractions of high purity (88.7 and 90.1%, namely) and intact activity rendering them easily used for medical purposes ([@b47-etm-0-0-8704]).

Usually, antibodies and/or their active fragments produced in mammals are engaged in diagnostic tests. However, due to animal welfare concerns, technical advantages and the high cost of production, alternatives to the production of antibodies in mammals have been investigated ([@b48-etm-0-0-8704]).

A constant goal for all current approaches involving IgY applications is to continuously optimize the production and purification of IgY antibodies from egg yolk to achieve high quantities and high active products for research and commercial use.

The most exploited immunoassay format with IgY remains the ELISA platform. In research as well as in clinic, one of the most effective and reliable method for rapid detection remains ELISA which is a versatile, flexible and sensitive method helpful in monitoring various pathologies including infectious diseases. Although IgG is the ʻ*weapon of choice*ʼ in designing such detection formats, in recent years IgY started to replace IgG because this molecule could be easily obtained, through a non-invasive way (basically extracted and purified from egg yolk of chickens immunized with recombinant proteins of interest), in adequate amounts and at lower costs than IgG.

IgY-based ELISA protocols retain all the features related to steps, reagents and applications of classic ELISA formats as IgY molecule can be enzymatically labeled (e.g., with horseradish peroxidase) and further applied in a wide range of immunoassay assessments such as bacterial toxins ([@b49-etm-0-0-8704]) or tumor antigen detection for cancer diagnosis ([@b50-etm-0-0-8704],[@b51-etm-0-0-8704]).

It is truly noticeable how versatile the use of IgY could be related to area of application, from viruses and bacteria to tumor antigens detection and quantification ([@b42-etm-0-0-8704]). Thus, diagnosis of cholera is somewhat an intricate attempt. Therefore, a recent study proposed IgY for targeting two proteins contained by the outer membrane of *V. cholera* (protein W and cytotoxin B). The study proposed two sensitive and specific sandwich ELISA formats, with no cross-reactivity with other bacteria. It was suggested that these IgY based ELISAs could constitute a rapid and specific detection tool for assessing *V. cholera* in different biological samples ([@b52-etm-0-0-8704]).

The use of IgY instead of mouse monoclonal IgG has the advantage of limiting the risk of false positive results as well as the reduced costs of the test. For example, an IgY-based sandwich ELISA was developed to quantify the total PSA level in human serum as an alternative to commercially available *in vitro* diagnosis tests ([@b53-etm-0-0-8704]).

Taking into account the latest concerns raised by respiratory infections of viral origin IgY might act as a very promising detection agent in this area. Thus, recent studies in swine model suggest that IgY molecule could bind specifically to viral nucleoprotein of influenza virus, which is known for exerting a key role in viral replication and therefore emphasizing the IgY effectiveness for influenza virus diagnosis ([@b48-etm-0-0-8704],[@b54-etm-0-0-8704]).

### Is there some spare room for other methodologies regarding IgY characterization in the last decade?

As already mentioned, IgY purification is currently achieved by conventional precipitation methods with ammonium sulphate or PEG and by chromatographic procedures. Sequential precipitation with 31% ammonium sulfate and 12% polyethylene glycol (PEG) produces IgY antibodies with above 95% purity without any loss in immunoreactivity ([@b55-etm-0-0-8704]).

Additional procedures of purification could be added to the separation methodologies, such as high-resolution chromatography accomplished for instance by multi-column systems such as NGC scout Bio-Rad system. Especially, but not restricted to mAbs, this system provides certain advantages over conventional chromatographic columns in terms of automatization, reproducibility and accessibility. During the process of obtaining biomolecules intended for biomedical application, high purity and intact functionality are the first considerations. Moreover a multi-column automated system could resolve several steps of purification in a single run, such as separation by affinity purification of a particular compound from original matrix, size exclusion to resolve aggregates and finally obtaining the product of interest with undamaged structure and function ([@b56-etm-0-0-8704]). By choosing the appropriate column the compound is loaded, purified and analyzed in a continuous run. High purification is further explored for designing platforms in which pathogens could be discriminated or when ELISA type platform are constructed intended for research or diagnosis.

An example of analyzing an IgY extract isolated from hen egg yolk by the Romanian Company Romvac S.A. using NGC scout Bio-Rad system is presented in [Fig. 1](#f1-etm-0-0-8704){ref-type="fig"}.

3. Passive immunization in infectious diseases
==============================================

### Passive immunization as general process

Passive immunization refers to administering already mature antibodies (Igs) in an attempt to rapidly overcome an infectious disease ([@b57-etm-0-0-8704]). Passive immunity can represent a natural phenomenon and/or can be artificially induced ([@b58-etm-0-0-8704]).

The natural passive immunity consists of maternal antibodies that are transferred to the offspring inducing protection before the offspring\'s self-immunity is built up. In birds, passive imunity is sustained by the IgY from the egg yolk which enters into the developing embryo ([@b59-etm-0-0-8704],[@b60-etm-0-0-8704]) and hence sustaining the first 2 weeks immunity in chickens, at the time when they start to build up their own immunity ([@b61-etm-0-0-8704]). In mammals passive immunity is sustained by maternal antibodies that are transferred to the fetus through the placenta, in humans this process is active especially during the last 3 months of pregnancy. Then the passive immunity is sustained by milk that also contains antibodies ([@b62-etm-0-0-8704]).

Artificially induced passive immunity is sustained by transferring antibodies by systemic, intravenous, or oral routes. Passive immunity is limited in time, thus, to sustain this immunity, preformed antibodies should be re-introduced ([@b63-etm-0-0-8704]).

A low-cost and rapid technology to obtain large scale passive immunity antibodies are IgY from egg yolk *via* hyperimmunization of chickens. Briefly this process involves hen immunization with specific antigens with a specific time schedule so that specific IgYs accumulate in the egg yolks. Afterwards, these IgY are extracted ([@b55-etm-0-0-8704],[@b64-etm-0-0-8704]). Passive immunization has a history of more than 100 years and has been used in both humans and animals ([@b67-etm-0-0-8704],[@b68-etm-0-0-8704]). Over 20 years ago, one of the first reports was published showing that intranasal antibody prophylaxis, was successful against viral respiratory infections in animal models \[e.g., against respiratory syncytial virus (RSV), influenza virus, Sendai virus\], and entered human clinical trials for influenza A and B viruses, Coxsackie virus, and rhinoviruses ([@b67-etm-0-0-8704]). Since then only non-viral IgY applications have been published such as oral administration of IgY preventing or treating diseases induced by *Streptococcus mutans* (dental carries), *E. coli*-diarrhea, gastritis (*H. pylori*), periodontitis (*P. gingivalis*) and oral candidiasis (*C. albicans*) infant rotavirus diarrhea ([@b23-etm-0-0-8704]). Rotavirus-induced diarrhea containing IgY (Rotamix IgY) was efficient in pediatric patients diagnosed with non-cholera enteric pathogen and was proven as a good adjuvant for the management of acute diarrhea ([@b68-etm-0-0-8704]). Therefore, IgY raised for specific viral respiratory infections should enter the spotlight again.

### IgY in passive immunization

IgY utilization in passive immunization has several advantages. Obtaining IgY from birds is ecologically friendly, the extract does not induce specific resistance and/or side effects and due to their specificity would not affect beneficial microbial population of the host.

Finally, if used as therapy in poultry and livestock IgY does not stay in the meat that is destined to human consumption as antibiotics do ([@b69-etm-0-0-8704]).

Using specific IgY in passive immunization is not age restricted, it can be applied to a wide range of ages, to a wide array of individuals characterized by patophysiological conditions, e.g., women in special conditions like pregnancy and/or immunodeficient patients.

IgY antibodies are naturally non-toxic and when lyophilized they can be stored in regular 4˚C or even at room temperature without losing their efficacy. Production costs are much lower when compared to standard mAbs and/or vaccines. Then storing can be done for months and transportation is thus facilitated in comparison to other biologicals ([@b70-etm-0-0-8704]). If not extracted the composition of IgY stored in eggs remains unchanged for at least 1 year at 4˚C ([@b71-etm-0-0-8704]). The product, IgY is collected from eggs and, therefore, does not impede the animal welfare.

From a molecular point of view, IgY has increased binding avidity for the antigens that generated them in comparison to mammalian IgG ([@b72-etm-0-0-8704]). Due to the evolutionary distance between mammals and birds IgY can be produced more easily against conserved mammalian molecules than IgG antibodies ([@b73-etm-0-0-8704]). For IgY generation a lower antigen load is necessary to induce the specific immune response ([@b69-etm-0-0-8704]).

For mass production, as the production of eggs for human consumption is already carried out on an industrial scale the production of eggs containing specific IgY already has its industrial backbone ([@b74-etm-0-0-8704]). One chicken can produce specific IgY of approximately 22 g/year ([@b45-etm-0-0-8704]).

4. Learning from severe acute respiratory syndrome
==================================================

Almost 20 years ago, coronaviruses (CoVs) were known to cause disease only in vertebrates but then, the severe acute respiratory syndrome (SARS)-CoV outburst in China showed the medical world that nature still has unknown paths ([@b75-etm-0-0-8704]). The disease spread rapidly worldwide, causing under 10,000 infections with a 10% mortality rate ([@b76-etm-0-0-8704],[@b77-etm-0-0-8704]). Through the SARS epidemy in China, passive immunization that used sera from recovered SARS patients offered positive results ([@b78-etm-0-0-8704]). IgY preparations were obtained with anti-SARS coronavirus action after isolation from egg yolk obtained from pathogen-free chickens immunized with SARS coronavirus antigen ([@b78-etm-0-0-8704]). It was reported that the obtained IgY had both high purity and biological activity. In cells model, the obtained IgY neutralized the SARS coronavirus. The preparation was stable upon lyophilization, that gave the product good manufacturing qualities ([@b78-etm-0-0-8704]). Anti-SARS IgY produced upon this procedure is a good candidate for anti SARS-CoV therapy. The authors stated that in case of an outbreak, a rapid intervention can be sustained by production of IgY antibodies. The production of an IgY antibody takes 1.5 months from hens vaccination to IgY production, so until a vaccination for an eventual outbreak is put in use, this rapid response can fulfill an urgent medical need. Moreover even when a proper vaccination is established, using this type of passive immunizations can significantly increase the control of the epidemic ([@b78-etm-0-0-8704]).

In 2007 a post-SARS outburst paper has shown that there is SARS-CoV viral reservoir that is actually a biological bomb waiting to explode ([@b79-etm-0-0-8704]) and now, after 15 years we are facing the biggest pandemic since the Spanish Flu in 1918. The medical world is ʻfast forwardingʼ research and translating research results to bedside. In this race, information changes almost in each hour. At present time, in the race to obtaining quickly a vaccine there are 44 products with 2 in clinical trial phase I ([@b80-etm-0-0-8704]), but these data will be obsolete in the forthcoming month. Nevertheless, until vaccination enters the application stages there are several steps and phases to be taken. Therefore, probably by the end of 2020 there will be the most accelerated approved vaccine. Alternative methods to overcome the outbreak and to therapeutically sustain infected patients are urgently needed. Passive immunization with plasma from recovered patients was already approved in USA ([@b81-etm-0-0-8704]). In this picture of passive immunization therapy IgY can have a future role.

[Table I](#tI-etm-0-0-8704){ref-type="table"} summarizes the main studies that used anti-viral respiratory infection IgY emphasizing on the experimental models, whether cellular or animal models.

5. Conclusions and future perspectives
======================================

Menacing viruses causing pandemics such as COVID-19 claim imperative future measures shaped in therapeutics and novel vaccines. Large-scale and coordinated effort are needed to minimize the impact of these threats on human health ([@b87-etm-0-0-8704],[@b88-etm-0-0-8704]). Joining these efforts, additional therapeutics open the perspective of using passive immunization with IgY on large scale as adjuvant therapy in viral respiratory infection. This endeavor should focus on aspects of increased production, improved hen immunization protocols, improved IgY extraction and increased antibody yield. Another point to be taken into consideration in the future is that chicken IgY have good monoclonality, therefore are more specific and have higher affinity in comparison to the ones obtained from immunizing mammals ([@b89-etm-0-0-8704]). As compared to IgGs, obtaining genetically engineered single chain fragment variable for IgY (IgY-scFv) is easier as these fragments were already implemented in diagnostics and therapy ([@b29-etm-0-0-8704],[@b90-etm-0-0-8704]).

Therefore, using specific IgY in viral respiratory infections have good premise and can be expanded to other infectious diseases.

In conclusion, far from being an obsolete chapter in immunodiagnostics, the IgY-technology is revised as a new frontier for research and clinic as already a wide range of IgY applications has been effectively confirmed in both human and animal health. The molecular particularities of IgY give them functional advantages recommending IgY as a versatile tool in biotechnological research, diagnostics and therapeutics. The main advantage is that IgY methodology is a reliable and nature friendly alternative for obtaining mammalian antibodies, as it is a non-invasive procedure. The aria of application is continuously enlarging from bacterial and viral infections to tumor biology. Specific anti-viral IgY has already been tested in several designs, thus it is worth pointing out that in the actual COVID-19 pandemic context, respiratory infections need an enlarged arsenal of therapeutic approaches and definitely IgY roles should be exploited in depth.
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![*NGC Chromatograms* of IgY extract isolated from hen egg yolk in comparison to standard protein cocktail. (A) Hen yolk egg IgY extract at 1 mg/ml concentration; (B) Standard protein cocktail for molecular weight identification. Column - size exclusion ENrich SEC 650, PBS elution, flow at 0.8 ml/min, absorbance registered 280 nm. IgY, immunoglobulin Y.](etm-20-01-0151-g00){#f1-etm-0-0-8704}

###### 

Main studies focusing on *in vitro* and *in vivo* models using anti-viral IgY.

  Pathogen                                IgY preparation                                               Model type                                    Effect                                                                                                                          Refs.
  --------------------------------------- ------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Pandemic influenza virus A/H1N1         Ostrich immunized with swine influenza virus vaccine strain   MDCK cells infected with pandemic virus       Neutralizing of viral infectivity in the cells                                                                                  ([@b82-etm-0-0-8704])
  Influenza B virus                       Hens immunized with IBV                                       MDCK cells BALB/c mouse model                 Neutralization of IBV in MDCK cells Reducing viral replication in the lungs                                                     ([@b83-etm-0-0-8704])
  Influenza A virus                       Hens immunized with H1N1 virus                                MDCK cells Mouse model                        Neutralizing of viral infectivity in the cells *In vivo* protection by reducing the infectious titer of the virus in the lung   ([@b84-etm-0-0-8704])
  Viruses H1N1, H3N2, and H5N1 strain     Hens immunized with whole inactivated H1N1, H3N2, and H5N1    MDCK cell BALB/c and C.B-17 mice              Neutralization of viruses in MDCK cells 100% protection against challenge with H5N1 and A/Puerto Rico/8/34 H1N1                 ([@b85-etm-0-0-8704])
  SARS                                    SPF chickens immunized with inactivated SARS coronavirus      VERO E6 cells                                 Neutralizing SARS coronavirus viral infectivity in the cells                                                                    ([@b78-etm-0-0-8704])
  BRSV related to human syncytial virus   Hens immunized with BRSV                                      MDCK cells infected with A51908 BRSV strain   Neutralization of viruses in MDCK cells                                                                                         ([@b86-etm-0-0-8704])

IgY, immunoglobulin Y; SARS, severe acute respiratory syndrome; SPF, specific pathogen-free; BRSV, bovine respiratory syncytial virus.
